|
Board of Directors
|
|
Dr Holdener has over 20
years of international pharmaceutical senior executive experience and
was most recently Chief Medical Officer of F. Hoffman-La Roche's Pharma
Division. He was also Global Head of Pharmaceutical Drug Development at
Roche where he was instrumental in establishing and expanding Roche's
therapeutic areas and in achieving several key international approvals
for oncology, rheumatology, and virology drugs such as MabThera. He
also led Roche's development operations in Japan for three years and
was a member of the Chugai Co. acquisition and integration team during
the Roche/Chugai merger in 2001. Dr Holdener holds a medical degree
from the University of Zurich and completed a two year clinical and
experimental fellowship in oncology at the University of Kansas Medical
School, USA.
|
|
Founder of NovImmune, and former professor and director of the
Department of Genetics and Microbiology, Faculty of Medicine,
University of Geneva, Bernard Mach is the inventor of cDNA cloning and
is specialized in the molecular biology of immune response genes. Bernard was co-founder and member of the SAB of Biogen (1978-1992). He was
Chairman of the Lombard Odier Immunology Fund Scientific Advisory Board
from 1994 to 2002. He is now Chairman of the SAB of Aravis Venture Associates. Former member of the
Board of Directors of Serono and former board member of Lonza as well
as Scientific Advisor to various institutes and companies. He was a
Member of the Swiss Science Council (1974-1984), is a special member of
the Swiss Academy of Medical Sciences and is a Member of the French
Academy of Sciences.
|
|
Jack Barbut joined NovImmune as CEO since 2001. He is the former President
and Chief Executive Officer of Synarc Inc, San Francisco, (1998-2000)
with more than 20 years of professional experience in clinical trials
management and drug development. Prior to joining Synarc, Jack Barbut
was the founder, Vice-Chairman and President of Clinical Services of
Chrysalis International, Inc., (1981-1998) a publicly (NASDAQ) traded
global full service, Contract Research Organization (CRO), with 450
employees, USD 60M in sales and USD 150 M in market capitalization when
it went public. Today it is part of MDS (NYSE), a global drug
development service company with USD 1.2 billion in sales and 11,000
employees. A Swiss citizen, Jack Barbut holds a MS in Electrical
Engineering and a ScD in Systems Engineering from the EPFL in Lausanne,
Switzerland.
|
|
Hans-Beat Gürtler has a commercial education and spent most of his
professional career with Ciba-Geigy and Novartis. He held various
positions with growing responsibility in the agricultural and animal
health field in Switzerland and abroad. From 1990 to 2002, he was
global CEO of Novartis Animal Health. In late 2002, he joined Varuma, a
private investor. He serves as a Board Member in various companies.
|
|
Dr. Joseph Manko is the CEO of BZ Bank. Prior to
BZ Bank, Dr. Manko had been with Deutsche Bank and Merrill Lynch in
London, New York and Hong Kong. Joseph Manko holds a Juris Doctor
degree from the University of Pennsylvania.
|
|
Martin Velasco is an
entrepreneur with extensive experience in the electronic, medical and biotech
areas. In the June 2000 Business Week
special report "The Stars of Europe", he was selected as one of the
leaders at the forefront of change in Europe.
Mr. Velasco was also dubbed the leading "Business Angel" by the Wall
Street Journal European edition in June 1999. On March 2004, Mr. Velasco was
elected "Business Angel of the year 2004" by the ASBAN and Bilanz. He serves on the
board/advisory board of several high-tech start-ups - including Speedlingua SA in which he serves as Chairman and CEO, Sumerian Networks of which he is Co-Founder and Board Member and AC-Immune in which he serves as Chairman, and Mediabolic in which he serves as Board member. Mr. Velasco is the Founder and Chairman of Infantia Foundation, a philanthropic organization aiding children in the developing world. He is member of the Executive Committee of the Positive Investment Initiative Association and Member of the Board and, a leading microfinance investment advisory company.
|
|
|
|
|
